Original filing text · Part I

Item 11 — Quantitative and Qualitative Disclosures About Market Risk

Mesoblast Limited · 20-F · FY 2026 · Period ended Jun 30, 2026

This is the extracted source text from the SEC filing. Formatting may differ from the original document.

For information about our exposure to market risk and how we manage this risk, see “Item 18. Financial Statements – Note 10.”